OCT4&SOX2‐specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem‐like cells in vitro and treating drug‐resistant lung cancer mice in vivo
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.27423
Abstract: This study aimed to investigate the synergistic effect of octamer‐binding transcription factor 4 and sex determining region Y‐box 2 (OCT4&SOX2)‐specific cytotoxic T lymphocytes (CTLs) and programmed cell death protein 1 (PD‐1) inhibitor on killing lung… read more here.
Keywords: inhibitor; group; oct4 sox2; ctls ... See more keywords
Silencing of the transcription factors Oct4, Sox2, Klf4, c-Myc or Nanog has different effect on teratoma growth.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2019.07.064
Abstract: Induced pluripotent stem cells (iPSC) have a great potential, but their clinical application depends on finding strategies to abolish their tumorigenic potential. The use of Oct4, Sox2, Klf4, c-Myc and Nanog to generate iPSC demonstrated… read more here.
Keywords: sox2 klf4; oct4 sox2; myc nanog; transcription factors ... See more keywords
OCT4 and SOX2 Work as Transcriptional Activators in Reprogramming Human Fibroblasts.
Sign Up to like & getrecommendations! Published in 2017 at "Cell reports"
DOI: 10.1016/j.celrep.2017.07.071
Abstract: SOX2 and OCT4, in conjunction with KLF4 and cMYC, are sufficient to reprogram human fibroblasts to induced pluripotent stem cells (iPSCs), but it is unclear if they function as transcriptional activators or as repressors. We… read more here.
Keywords: sox2 work; human fibroblasts; sox2 vp16; oct4 sox2 ... See more keywords
Pluripotency reprogramming by competent and incompetent POU factors uncovers temporal dependency for Oct4 and Sox2
Sign Up to like & getrecommendations! Published in 2019 at "Nature Communications"
DOI: 10.1038/s41467-019-11054-7
Abstract: Oct4, along with Sox2 and Klf4 (SK), can induce pluripotency but structurally similar factors like Oct6 cannot. To decode why Oct4 has this unique ability, we compare Oct4-binding, accessibility patterns and transcriptional waves with Oct6… read more here.
Keywords: pluripotency; oct4 sox2; chromatin opening; pluripotency reprogramming ... See more keywords
YY1 Is Required for Posttranscriptional Stability of SOX2 and OCT4 Proteins.
Sign Up to like & getrecommendations! Published in 2017 at "Cellular reprogramming"
DOI: 10.1089/cell.2017.0002
Abstract: Yinyang1 (YY1) participates in protein-DNA, protein-RNA, and protein-protein interactions and regulates developmental processes and disease mechanisms. YY1 interactions regulate a range of important biological functions, including oocyte maturation, epithelial to mesenchymal transition, and vascular endothelial… read more here.
Keywords: protein; oct4 sox2; sox2; yy1 ... See more keywords
Mechanisms of OCT4-SOX2 motif readout on nucleosomes
Sign Up to like & getrecommendations! Published in 2020 at "Science"
DOI: 10.1126/science.abb0074
Abstract: Engaging the nucleosome Cell identity is defined by gene expression patterns that are established through the binding of specific transcription factors. However, nucleosomal units limit access of transcription factors to specific DNA motifs within the… read more here.
Keywords: motif; microscopy; dna; oct4 sox2 ... See more keywords
OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.781093
Abstract: Purpose This study aimed to investigate the effect of OCT4&SOX2 specific cytotoxic T lymphocytes (CTLs) plus programmed cell death protein-1 (PD-1) inhibitor (nivolumab) on treating breast cancer stem-like cells (BCSCs) in vitro and drug-resistance breast… read more here.
Keywords: breast cancer; oct4 sox2; inhibitor nivolumab;